(2026). Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica - the Hematology journal.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Tumor Burden-guided Dosing Contributes to Mitigation of Immunotoxicities Following Treatment with Obecabtagene Autoleucel in Adult Patients with Relapsed/refractory B-cell Acute Lymphoblastic Leukemia."
Haematologica - the Hematology Journal 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Tumor Burden-guided Dosing Contributes to Mitigation of Immunotoxicities Following Treatment with Obecabtagene Autoleucel in Adult Patients with Relapsed/refractory B-cell Acute Lymphoblastic Leukemia."
Haematologica - the Hematology Journal, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.